Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KIT mutations and expression

BackgroundGastrointestinal stromal tumours (GISTs) represent a heterogeneous group of tumours of mesenchymal origin characterized by gain-of-function mutations in KIT or PDGFRA of the type III receptor tyrosine kinase family. Although mutations in either receptor are thought to drive an early oncogenic event through similar pathways, two previous studies reported the mutation-specific gene expression profiles. However, their further conclusions were rather discordant. To clarify the molecular characteristics of differentially expressed genes according to GIST receptor mutations, we combined microarray-based analysis with detailed functional annotations.MethodsTotal RNA was isolated from 29 frozen gastric GISTs and processed for hybridization on GENECHIP® HG-U133 Plus 2.0 microarrays (Affymetrix). KIT and PDGFRA were analyzed by sequencing, while related mRNA levels were analyzed by quantitative RT-PCR.ResultsFifteen and eleven tumours possessed mutations in KIT and PDGFRA, respectively; no mutation was found in three tumours. Gene expression analysis identified no discriminative profiles associated with clinical or pathological parameters, even though expression of hundreds of genes differentiated tumour receptor mutation and expression status. Functional features of genes differentially expressed between the two groups of GISTs suggested alterations in angiogenesis and G-protein-related and calcium signalling.ConclusionOur study has identified novel molecular elements likely to be involved in receptor-dependent GIST development and allowed confirmation of previously published results. These elements may be potential therapeutic targets and novel markers of KIT mutation status.

[1]  J. Schlessinger,et al.  Signaling by Receptor Tyrosine Kinases , 1993 .

[2]  D. Longo,et al.  JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor. , 1996, Blood.

[3]  F. McCormick,et al.  Regulation of Epidermal Growth Factor Receptor Signaling by Phosphorylation of the Ras Exchange Factor hSOS1 (*) , 1996, The Journal of Biological Chemistry.

[4]  S. Ward,et al.  Development and plasticity of interstitial cells of Cajal , 1999, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[5]  Dipanwita Roy Chowdhury,et al.  Human protein reference database as a discovery resource for proteomics , 2004, Nucleic Acids Res..

[6]  J. Schlessinger Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[7]  J. Lasota,et al.  KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). , 2006, Seminars in diagnostic pathology.

[8]  W. R. Burack,et al.  The activating dual phosphorylation of MAPK by MEK is nonprocessive. , 1997, Biochemistry.

[9]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[10]  J. Reguła,et al.  Molecular defense mechanisms of Barrett’s metaplasia estimated by an integrative genomics , 2007, Journal of Molecular Medicine.

[11]  S. Hirota,et al.  Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. , 2003, Gastroenterology.

[12]  A. Bernstein,et al.  Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice--evidence for an impaired c-kit kinase in mutant mice. , 1989, Genes & development.

[13]  W. H. Kim,et al.  Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining , 2007, Journal of Clinical Pathology.

[14]  P. Besmer The kit ligand encoded at the murine Steel locus: a pleiotropic growth and differentiation factor. , 1991, Current opinion in cell biology.

[15]  M. Reyland Protein kinase C isoforms: Multi-functional regulators of cell life and death. , 2009, Frontiers in bioscience.

[16]  John E. Murphy,et al.  A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family , 1986, Nature.

[17]  N. Anderson,et al.  The isoform-specific regulation of apoptosis by protein kinase C , 2003, Cellular and Molecular Life Sciences CMLS.

[18]  J. Pfeiffer,et al.  Wortmannin-sensitive phosphorylation, translocation, and activation of PLCgamma1, but not PLCgamma2, in antigen-stimulated RBL-2H3 mast cells. , 1998, Molecular biology of the cell.

[19]  P. Besmer,et al.  Kit signaling through PI 3‐kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation , 1998, The EMBO journal.

[20]  J. Fletcher,et al.  Biology of gastrointestinal stromal tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Tina Hernandez-Boussard,et al.  Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles , 2004, Oncogene.

[22]  Hoguen Kim,et al.  Differentially expressed proteins in gastrointestinal stromal tumors with KIT and PDGFRA mutations , 2006, Proteomics.

[23]  Don Gilbert,et al.  Biomolecular Interaction Network Database , 2005, Briefings Bioinform..

[24]  E. Liu,et al.  Correlation of KIT and platelet-derived growth factor receptor α mutations with gene activation and expression profiles in gastrointestinal stromal tumors , 2005, Oncogene.

[25]  Mike Tyers,et al.  BioGRID: a general repository for interaction datasets , 2005, Nucleic Acids Res..

[26]  P. Nyckowski,et al.  Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors. , 2007, Medical science monitor : international medical journal of experimental and clinical research.

[27]  P. Thall,et al.  Association of Intratumoral Vascular Endothelial Growth Factor Expression and Clinical Outcome for Patients with Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate , 2007, Clinical Cancer Research.

[28]  D. Fabbro,et al.  Classical PKC isoforms in cancer. , 2007, Pharmacological research.

[29]  S. Steigen,et al.  Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors , 2007, Laboratory Investigation.

[30]  L. Koniaris,et al.  Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. , 2006, Journal of the American College of Surgeons.

[31]  F. Galibert,et al.  Molecular evolution of the genes encoding receptor tyrosine kinase with immunoglobulinlike domains , 1995, Journal of Molecular Evolution.

[32]  A. Mui,et al.  The role of STATs in proliferation, differentiation, and apoptosis , 1999, Cellular and Molecular Life Sciences CMLS.

[33]  J. Lasota,et al.  Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis , 2000, Virchows Archiv.

[34]  P. Dentelli,et al.  STAT Protein Recruitment and Activation in c-Kit Deletion Mutants* , 1999, Journal of Biological Chemistry.

[35]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[36]  A. Ullrich,et al.  Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. , 1987, The EMBO journal.

[37]  I. Kerr,et al.  Jaks and Stats in signaling by the cytokine receptor superfamily. , 1995, Trends in genetics : TIG.

[38]  L. Kindblom,et al.  Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. , 1998, The American journal of pathology.

[39]  H. El‐Serag,et al.  The Epidemiology of Malignant Gastrointestinal Stromal Tumors: An Analysis of 1,458 Cases from 1992 to 2000 , 2005, The American Journal of Gastroenterology.

[40]  Tissue microarrays characterise the clinical significance of a VEGF-A protein expression signature in gastrointestinal stromal tumours , 2007, British Journal of Cancer.

[41]  J. Pfeiffer,et al.  Wortmannin-Sensitive Phosphorylation, Translocation, and Activation of PLCγ1, but Not PLCγ2, in Antigen-stimulated RBL-2H3 Mast Cells , 1998 .

[42]  J. Darnell,et al.  Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. , 1995, Annual review of biochemistry.